To view the complete article click
here (pdf format)
ABSTRACT
This 5-part Lung Cancer Supplement includes
an overview of what is new in lung cancer from the most recent ESMO
meeting (October 2011), authored by Gwyn Bebb, MA, BMBCh, PhD, FRCPC.
A summary by Peter Ellis, MBBS, MMed, PhD, FRACP, PRCPC, on the
current challenges posed by metastatic NSCLC reflects the many strides
that have been made in improving treatment options. Christopher
W. Lee, MD, FRCPC, and Nimira Alimohamed, MD, with Gwyn Bebb, MA,
BMBCh, PhD, FRCPC, address mesothelioma and small cell lung cancer
respectively, malignancies where progress seems disappointingly
slower. Julia Devonish, PhD, Nicole Culos-Reed, PhD, and Gwyn Bebb,
MA, BMBCh, PhD, FRCPC, review the emerging role of physical activity
in lung cancer, an intervention that is validated in other cancers,
but has yet to make useful inroads in lung cancer management. The
fact that this topic is now entering consciousness is testament
in itself that expectations in lung cancer management are growing.
We need to tout our successes in lung cancer treatment and let our
marathon-running lung cancer survivors start to take the limelight.
Keywords
lung cancer, pulmonary cancer, small-cell
lung cancer, non-small cell lung cancer, mesothelioma, physical
activity, exercise, chemotherapy, radiotherapy.
16TH
ECCO/36TH ESMO EUROPEAN CANCER CONGRESS, STOCKHOLM
Update on research and management implications
in NSCLC and SCLC
Gwyn Bebb, MA, BMBCh, PhD, FRCPC
SYSTEMIC
THERAPY FOR NON-SMALL CELL LUNG CANCER IN 2011
Multiple options are linked to improved
survival and quality of life
Peter M. Ellis, MBBS, MMed, PhD, FRACP,
FRCPC
PHYSICAL
ACTIVITY IN LUNG CANCER
Emerging data links physical activity
with long-term benefits
Julia Devonish, PhD; Nicole Culos-Reed,
PhD; Gwyn Bebb, MA, BMBCh, PhD, FRCPC
MESOTHELIOMA
UPDATE
Aggressive management under debate
Christopher W. Lee, MD FRCPC
SMALL
CELL LUNG CANCER AND PROGRESS OVER 20 YEARS
Effort: B Achievement: F
Nimira Alimohamed MD; Gwyn Bebb, MA,
BMBCh, PhD, FRCPC
Sponsorship of distribution of the Lung Cancer UPDATE
Part 1 supplement to Oncology Exchange’s November 2011
issue is funded by Boehringer Ingelheim Canada Ltd./Ltee.
To view the complete article click
here (pdf format)
|
